Palliative Medical Management of Inoperable Malignant Bowel Obstruction With “Triple Therapy”: Dexamethasone, Octreotide, and Metoclopramide

American Journal of Hospice and Palliative Medicine - Tập 38 Số 4 - Trang 340-345 - 2021
Winston Wey1,2, Moeena Mian1,2, Rebecca Calabrese3,2, Eric Hansen3,2, Michelle Walter3,2, Chong Wang2, Austin Miller2, Amy A. Case3,2
1Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA
2Department of Supportive and Palliative Care, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
3Department of Geriatrics and Palliative Medicine, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA

Tóm tắt

Context: Malignant bowel obstruction (MBO) is a complication of advanced malignancy. For inoperable patients, symptoms are often treated using analgesics, anticholinergics, and anti-emetics. There are, however, few published guidelines for the medical management of MBO. Objective: To measure the effect of the combination of dexamethasone, octreotide, and metoclopramide (“triple therapy”) in patients with MBO, compared to patients who received none of the 3 medications (“no drug therapy”). Methods: A retrospective cohort study of patients with MBO admitted in a single-center comprehensive cancer center. Patients who received dexamethasone, octreotide, and metoclopramide during their hospitalization for treatment of inoperable MBO were selected for analysis. Patients were excluded if they received a venting gastric tube. Rate of de-obstruction as well as time to de-obstruction were measured. Results: There were 20 patients identified who received all 3 drugs of interest, and 29 patients identified who received none of the 3 medications. There was no statistically significant difference in rates of de-obstruction between the 2 groups, though there was a non-significant trend toward patients who received triple therapy were more likely to reach de-obstruction, compared to patients who had no drug therapy (95% vs. 83%, p = 0.379); there was no significant difference in adjusted analysis. Conclusion: In patients with inoperable MBO, there was no statistically significant difference in rates of de-obstruction with triple drug therapy compared to patients who received none of the 3 drugs, though the study may not have been powered to detect a difference and further investigation is warranted.

Từ khóa


Tài liệu tham khảo

Zucchi E, 2016, Support Care Cancer, 24, 2877

10.1016/j.jpainsymman.2007.04.011

10.2147/CMAR.S29297

10.1016/j.jamcollsurg.2017.04.033

10.1007/s005200000198

10.1001/jamasurg.2013.4059

10.1186/s12885-018-5108-9

10.1016/j.jpainsymman.2013.08.022

10.1016/j.jpainsymman.2006.06.014

10.1016/j.jpainsymman.2014.09.013

10.1007/s005200050283

10.1191/026921698666334766

10.1191/026921600669298725

10.1002/14651858.CD002764

Isbister WH, 1990, J R Coll Surg Edinb, 35, 369

10.1177/1049909115569047

10.1080/00273171.2011.568786

10.1016/j.medcli.2010.03.002

10.1007/s11605-007-0423-5

10.1097/TA.0b013e31816f709e

Metoclopramide [package insert]. Baxter Healthcare Corporation; 2010.